This study investigated the inhibitory effects of propranolol on epithelial-mesenchymal transition (EMT) in breast cancer cells. It focused on the 4T1 murine mammary adenocarcinoma cell line. The study identified miR-499-5p and its target gene Sox6 as key factors in EMT inhibited by propranolol. Results showed that propranolol treatment reduced EMT and metastasis by increasing miR-499-5p levels and decreasing Sox6 expression in breast cancer cells. The findings suggest propranolol may have therapeutic potential for breast cancer treatment by inhibiting EMT.